Tim Xu, MD, Arix Bioscience plc (LSE:ARIX) discusses recent Phase 2 data from Arix portfolio company Amplyx Pharmaceuticals and why anti-infectives are especially important now during the pandemic.
Amplyx Pharmaceuticals is a clinical-stage company, developing innovative therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. These can be people affected by fungal infections caused by pathogens such as Candida, Aspergillus and rare molds, as well as patients at risk for nephropathy and hemorrhagic cystitis caused by the BK virus.
Their product candidates include fosmanogepix (APX001) and MAU868, which have the potential to protect those who are vulnerable to secondary illnesses and transform standard of care treatments for immunocompromised patients.
Amplyx recently announced positive topline data following the completion of its Phase 2 clinical trial of fosmanogepix as a first-line treatment for patients with invasive fungal infections caused by Candida. The trial met its primary efficacy endpoint, demonstrating a treatment success rate of 80%. Fosmanogepix was well tolerated with no treatment-related serious adverse events or discontinuations.